Canopy Growth (CGC) Return on Capital Employed (2020 - 2026)
Canopy Growth (CGC) posted Return on Capital Employed of 13.14% for Q4 2025, down 6.84% sequentially from 12.3% in Q3 2025, and up 637.0% YoY from 1.78% in Q4 2024.
Canopy Growth (CGC) Return on Capital Employed (2020 - 2026) Analysis & Trends
Canopy Growth has reported Return on Capital Employed for 6 years, with the latest figure at 13.14% in Q4 2025.
- Quarterly Return on Capital Employed rose 637.0% year-over-year to 13.14% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 13.14% (up 637.0% YoY) and the FY2026 annual result came in at 17.11%, down 593.0% from the prior year.
- Return on Capital Employed retreated to 13.14% in Q4 2025 per CGC's latest filing, from 12.3% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.3% in Q3 2025 and troughed at 147.1% in Q1 2023.
- A 5-year average of 40.38% and a median of 19.51% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 12928 bps in 2023, then soared 12401 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 12.82% in 2021, then sank by 745 bps to 108.37% in 2022, then jumped by 52 bps to 51.81% in 2023, then soared by 62 bps to 19.51% in 2024, then soared by 33 bps to 13.14% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 13.14%, 12.3%, and 15.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | -13.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.38% |
| Dec 31, 2025 | -13.14% |
| Sep 30, 2025 | -12.30% |
| Jun 30, 2025 | -15.60% |
| Dec 31, 2024 | -19.51% |
| Sep 30, 2024 | -26.15% |
| Jun 30, 2024 | -19.17% |
| Mar 31, 2024 | -23.10% |
| Dec 31, 2023 | -51.81% |
| Sep 30, 2023 | -41.69% |
| Jun 30, 2023 | -46.39% |
| Mar 31, 2023 | -147.10% |
| Dec 31, 2022 | -108.37% |
| Sep 30, 2022 | -92.24% |
| Jun 30, 2022 | -64.32% |
| Mar 31, 2022 | -17.82% |
| Dec 31, 2021 | -12.82% |
| Sep 30, 2021 | -17.92% |
| Jun 30, 2021 | -18.32% |
| Mar 31, 2021 | -19.35% |